MedTrace Logo

Parkinson's Disease (PD) Treated With Focused Ultrasound Subthalamotomy at an Early Stage

NCT04692116 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-06-07

No results posted yet for this study

Summary

Parkinson's disease (PD) is a common, progressive, incurable neurodegenerative disease that can result in severe disability and impairment in health-related quality of life. Current medical and surgical therapies are aimed toward maximal symptom relief with minimal associated side effects or morbidity. It is generally accepted that a well-placed stereotactic lesion is comparable in its magnitude of clinical effect to the high frequency electrical stimulation of the same target.

Exablate Neuro is intended to treat movement disorders with unilateral ablation of targets in the thalamus, subthalamic nucleus and globus pallidus nuclei.

With the ExAblate system, transcranial high-intensity focused ultrasound has been coupled with high resolution MRI to provide precise, consistent treatments that can be monitored throughout the procedures.

Conditions

  • Parkinson Disease

Interventions

DEVICE

ExAblate treatment

Subthalamotomy using the ExAblate

Sponsors & Collaborators

  • Syntax for Science, S.L

    collaborator INDUSTRY

  • Fundación de investigación HM

    lead OTHER

Principal Investigators

  • José Obeso, MD · Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-11-12
Completion
2021-11-12

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04692116 on ClinicalTrials.gov